NEW YORK, April 3, 2017 /PRNewswire/ --
On Friday, March 31, 2017, US markets saw broad based losses with five out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of last Friday's session. The NASDAQ Composite ended the day at 5,911.74, down 0.04%; the Dow Jones Industrial Average edged 0.31% lower, to finish at 20,663.22; and the S&P 500 closed at 2,362.72, down 0.23%. This Monday morning, Stock-Callers.com looks at the performance of these four Biotechnology stocks: Alcobra Ltd (NASDAQ: ADHD), Cerus Corporation (NASDAQ: CERS), 22nd Century Group Inc. (NYSE MKT: XXII), and Moleculin Biotech Inc. (NASDAQ: MBRX). You can access our complimentary research reports on these stocks now at:
Tel Aviv, Israel headquartered Alcobra Ltd's stock closed the day flat at $1.14. The stock recorded a trading volume of 236,512 shares. Alcobra's shares are trading 3.49% and 59.42% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which focuses on the development and commercialization of oral drug candidates, have a Relative Strength Index (RSI) of 41.88. Visit us today and download your complete report on ADHD for free at:
On Friday, shares in Concord, California headquartered Cerus Corp. ended the session 0.23% higher at $4.45 with a total volume of 836,895 shares traded. Cerus' shares have advanced 0.91% in the last one month and 2.30% in the previous three months. The stock is trading 5.79% above its 50-day moving average. Moreover, shares of the Company, which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety, have an RSI of 59.54. The complimentary research report on CERS can be accessed at:
On Friday, shares in Clarence, New York headquartered 22nd Century Group Inc. recorded a trading volume of 1.34 million shares, which was higher than their three months average volume of 919,960 shares. The stock ended the day 5.60% lower at $1.18. 22nd Century's stock has gained 26.88% in the last one month and 8.26% in the previous three months. Furthermore, the stock has surged 47.46% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 22.95% and 14.80%, respectively. Moreover, shares of 22nd Century, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have an RSI of 66.64. Register for free on Stock-Callers.com and download the PDF research report on XXII at:
Houston, Texas headquartered Moleculin Biotech Inc.'s stock finished Friday's session 8.33% higher at $1.17 with a total volume of 574,030 shares traded. Moleculin Biotech's shares have advanced 5.41% in the last one month. The Company's shares are trading below its 50-day and 200-day moving averages by 16.83% and 69.75%, respectively. Shares of Moleculin Biotech, which focuses on the development of anti-cancer drug candidates, have an RSI of 44.58. Get free access to your research report on MBRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA